The differentiation between AIS, ICH, and SM patients was reported in a study with 1,308 participants based on the blood biomarkers NT-proBNP and endostatin combined with other variables, yielding a positive predictive value of 80.8%, which was not sufficient for making an exact diagnosis (34). This evidence concerns the gene COL18A1 and androgen insensitivity syndrome.